메뉴 건너뛰기
Clinical Nuclear Medicine
Volumn 32, Issue 12, 2007, Pages 952-953
In-111 ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 ibritumomab treatment in a patient with mantle cell lymphoma
Author keywords

Fluorodeoxyglucose; In 111 ibritumomab tiuxetan; Non Hodgkin lymphoma; PET CT; Positron emission tomography; Radioimmunotherapy
Indexed keywords

FLUORODEOXYGLUCOSE; IBRITUMOMAB IN 111; IBRITUMOMAB TIUXETAN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;
EID: 36349031744     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31815976a5     Document Type: Article
Times cited : (3)
References (9)
  • 1
    • 0036840133 scopus 로고    scopus 로고
    • Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice
    • Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43:1507-1529.
    • (2002) J Nucl Med , vol.43 , pp. 1507-1529
    • Juweid, M.E.1
  • 2
    • 0037093241 scopus 로고    scopus 로고
    • Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular or transformed B-cell non-Hodgkin's lymphoma
    • Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
    • (2002) J Clin Oncol , vol.20 , pp. 2453-2463
    • Witzig, T.E.1    Gordon, L.I.2    Cabanillas, F.3
  • 3
    • 33644521774 scopus 로고    scopus 로고
    • Radioimmunotherapy for non-Hodgkin lymphoma: Historical development and current status
    • Emmanouilides C. Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status. Rev Esp Med Nucl. 2006;25:42-54.
    • (2006) Rev Esp Med Nucl , vol.25 , pp. 42-54
    • Emmanouilides, C.1
  • 4
    • 33746517933 scopus 로고    scopus 로고
    • Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas
    • Mikhaeel NG. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging. 2006;33:S22-S26.
    • (2006) Eur J Nucl Med Mol Imaging , vol.33
    • Mikhaeel, N.G.1
  • 5
    • 33644832630 scopus 로고    scopus 로고
    • The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: Results from a zevalin imaging registry
    • Conti PS, White C, Pieslor P, et al. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a zevalin imaging registry. J Nucl Med. 2005;46:1812-1818.
    • (2005) J Nucl Med , vol.46 , pp. 1812-1818
    • Conti, P.S.1    White, C.2    Pieslor, P.3
  • 6
    • 0036168934 scopus 로고    scopus 로고
    • Administration Guidelines for Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    • Wagner HN, Wiseman GA, Marcus CS, et al. Administration Guidelines for Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
    • (2002) J Nucl Med , vol.43 , pp. 267-272
    • Wagner, H.N.1    Wiseman, G.A.2    Marcus, C.S.3
  • 7
    • 0842324899 scopus 로고    scopus 로고
    • Imaging and dosing radioimmunotherapy with yttrium 90-ibritumomab tiuxetan (Zevalin)
    • Spies SM. Imaging and dosing radioimmunotherapy with yttrium 90-ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004;34(1, suppl 1):10-13.
    • (2004) Semin Nucl Med , vol.34 , Issue.1 and SUPPL. 1 , pp. 10-13
    • Spies, S.M.1
  • 8
    • 33947273534 scopus 로고    scopus 로고
    • EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90-Y-radiolabelled ibritumomab tiuxetan (Zevalin)
    • Tennvall J, Fischer M, Bischof-Delayone A, et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90-Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34:616-622.
    • (2007) Eur J Nucl Med Mol Imaging , vol.34 , pp. 616-622
    • Tennvall, J.1    Fischer, M.2    Bischof-Delayone, A.3
  • 9
    • 33644541478 scopus 로고    scopus 로고
    • Radioimmunotherapy with 90-Y-ibritumomab tiuxetan in lymphomas
    • Setoain X, López-Guillermo A, Ruiz A, et al. Radioimmunotherapy with 90-Y-ibritumomab tiuxetan in lymphomas. Rev Esp Med Nucl. 2006;25:55-68.
    • (2006) Rev Esp Med Nucl , vol.25 , pp. 55-68
    • Setoain, X.1    López-Guillermo, A.2    Ruiz, A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.